Clinical trial
Bevacizumab to Treat Inflammatory Breast Cancer or Locally Advanced Breast…
NCT00016549 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00016549 |
|---|---|
| Title | Bevacizumab to Treat Inflammatory Breast Cancer or Locally Advanced Breast Cancer |
| Official title | A Pilot Study to Evaluate Angiogenesis After Treatment With Bevacizumab (Anti-VEGF Humanized Monoclonal Antibody) in Previously Untreated Patients With Inflammatory Breast Cancer or Locally Advanced Breast Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Biological |
| Interventions | Bevacizumab |
| Enrollment | 21 |
| Start date | May 13, 2001 |
| Primary completion | Jan 29, 2007 |
| Completion | Jan 29, 2007 |
| First posted | May 17, 2001 |
| Last update posted | Jul 2, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: